ERBB2 and cancer: The down-regulation of EGFR enhanced the sensitivity to taxol, gefitinib and trastuzumab (Figure 11A), increased caspase-3 activity in response to these anti-cancer drugs in Malme3MR cells (Figure 11B), but not the expression of CAGE or HER2 (Figure 11B), and induced cleavage of PARP in response to taxol, gefitinib and trastuzumab in Malme3MR cells (Figure 11C).